Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

More than 90 genes can cause retinitis pigmentosa. Celliaz, a biotech in Daejeon, South Korea, built on research from KAIST, is developing a gene therapy that doesn't try to correct any of them.

On November 12, Andelyn Biosciences and Celliaz announced a strategic partnership to advance that therapy, CLZ002, an investigational adeno-associated virus (AAV)-based gene therapy built on an AAV2 capsid. Andelyn, a US-based cell and gene therapy contract development and manufacturing organization (CDMO), is handling Celliaz's development and manufacturing from start to finish on its proprietary AAV Curator Suspension Platform. Celliaz will make both its AAV2 vector and its plasmids on that platform, supplying IND-enabling studies as well as a planned Phase 1/2 trial.

The design of the drug is what makes the deal interesting. If CLZ002 works as intended, one manufacturing process could serve patients across many genetic causes of the disease, a group that gene-specific programs would split into separate products. That process is being chosen now, before the first regulatory filing.

A repair pathway in place of 90 gene targets

Retinitis pigmentosa is a group of inherited retinal diseases that cause progressive vision loss and affect more than 3 million people worldwide, Andelyn's release says, and treatment options remain limited. Celliaz's premise centers on Müller glia, retinal cells that keep a latent ability to regenerate tissue. According to the company, a protein called PROX1 moves into those cells from neighboring retinal cells and suppresses that regenerative activity. CLZ002 is designed to block the transfer, with the aim of letting the retina's own repair capacity resume.

Celliaz CEO Kyung Hwa Kang linked the approach to the genetics of the disease. Kang said that because RP can arise from mutations in more than 90 genes, it is hard to build gene-specific therapies that reach a broad patient population.

The reasoning that follows is MarketScale's, not the companies'. Mutation-specific products spread development and manufacturing risk across many small programs. A gene-agnostic product built on a single AAV2 vector concentrates that risk in one process. If CLZ002 works as intended, the yield, purity and consistency of that process would determine supply for patients who would otherwise be split across dozens of programs, so decisions made during IND-enabling work could matter longer than they usually do for an early-phase asset.

Plasmid to vector under one roof

Celliaz is buying more than fill capacity. Contract Pharma's Charlie Sternberg reported that Celliaz picked Andelyn for both process development and manufacturing. Kang specifically cited Andelyn's integrated plasmid and viral vector manufacturing, along with its ophthalmic and rare disease AAV experience. Keeping plasmid and vector manufacturing with one provider could remove a supplier handoff from the chain.

Andelyn's commercial chief, Matt Niloff, said the company supports client INDs with AAV expertise that includes ophthalmology and rare disease programs, and that Celliaz adds to its work supporting multiple other South Korean programs. For outsourcing leads at Asian biotechs, that could matter: a US CDMO that already serves several South Korean programs may have some experience supporting sponsors on the other side of the Pacific.

Andelyn says in its company description that it has made clinical and commercial material across more than 500 cGMP batches and 85 global clinical trials, among them an FDA-approved AAV gene therapy. For a sponsor at Celliaz's stage, that suggests the manufacturer has already supported a product through approval. Its capabilities include cGMP manufacturing for both suspension and adherent processes, and it offers tech transfer within an established client program as an alternative to developing processes on its Curator platforms.

Where the manufacturing read could matter less

The strongest objection is biological. If the mechanism doesn't hold up in patients, the broad-population argument goes away, and this becomes an ordinary early-phase supply contract scaled to a Phase 1/2 study.

Neither company disclosed commercial terms, reserved capacity or process targets such as scale or yield. Outside readers can't tell how much of the process Celliaz will own or how portable it is. For other sponsors, that makes this deal a reference point for scope only, not for pricing or contract structure.

Questions for a sponsor choosing an AAV partner before the IND

For a CMC or outsourcing lead at an early-stage gene therapy company, especially one whose product is meant to serve several genetic subgroups, the Celliaz arrangement suggests a few questions to settle before a platform contract is signed. These are editorial recommendations drawn from the deal's stated scope, not requirements either company has published.

• If process development happens on a proprietary platform, who owns the resulting process, and how would it transfer to a second site if clinical demand grew?
• Does the provider's phase-appropriate quality system carry IND-enabling lots into Phase 1/2 clinical supply without a process change that would require new comparability work?
• How will clinical material reach trial sites outside the US?

The first public checkpoint will be the IND filing, and neither company has dated it. The more telling signal comes later, from the planned Phase 1/2 trial. That study could be the first real test of the gene-agnostic claim, and it could show whether one AAV2 process can actually serve the population Celliaz is aiming for.